Is 'off-protocol' chemotherapy for androgen-independent carcinoma of prostate warranted?

S. Mani, N. J. Vogelzang

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


It is acceptable to treat HRPC patients with off-protocol chemotherapy if these patients do not accept protocol therapy or are ineligible for such therapy. The choice of cytotoxic agent needs to be individually assessed, depending on range of tolerable toxicities and personal preferences of the physician and patient. At the present time, single-agent therapy with oral or intravenous cyclophosphamide or mitoxantrone/prednisone may offer optimal palliation without undue side effects in a predictable number of patients.

Original languageEnglish (US)
Pages (from-to)749-768
Number of pages20
JournalHematology/Oncology Clinics of North America
Issue number3
StatePublished - 1996
Externally publishedYes

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Is 'off-protocol' chemotherapy for androgen-independent carcinoma of prostate warranted?'. Together they form a unique fingerprint.

Cite this